Board of Directors


Co-founder, Chief Executive Officer & Director

With more than thirty years of executive, general management, business development, sales, marketing, and technology commercialization experience, Mr. Sharp’s career spans private venture-backed businesses, mid-size and Fortune 100 public companies in the medical device, diagnostics and life science tools and services markets. Mr. Sharp has served in senior leadership roles with five venture-backed companies—as Chief Executive Officer of CYTOO, Inc. and ArunA Biomedical, Chief Commercial Officer of BioProcessors Corporation (acquired by Seahorse Biosciences), SVP Business Development of Cellomics (acquired by Fisher International), and VP Business Development of Gentra Systems (acquired by Qiagen). Earlier career includes senior leadership roles with Life Technologies, General Manager of Terumo Medical, Vice President of Sales and Marketing at Heraeus Instruments and roles of increasing responsibility within the diagnostics business of Baxter Healthcare and a medical device subsidiary of Eli Lilly. Mr. Sharp has successfully commercialized more than 500 products and services. Earned M.S. and B.A. degrees from the Pennsylvania State University.


Co-founder, Director, Scientific Advisor

Dr. Demirci is a Professor with tenure and Co-division Chief, Canary Center for Cancer Early Detection, Department of Radiology at Stanford University. Before moving to Stanford, he was Associate Professor of Medicine and Health Sciences and Technology at the Harvard Medical School (HMS) and Massachusetts Institute of Technology (MIT). He received a bachelor’s degree (summa cum laude) from the University of Michigan, Ann Arbor; master’s degrees in Electrical Engineering in 2001 and in Management Science and Engineering in 2005, as well as a PH.D. in Electrical Engineering in 2005 all from Stanford University. Dr. Demirci is an academic entrepreneur with seminal contributions to the development of innovative microfluidic platform technologies in medicine for broad applications in fertility, cell sorting, and point-of-care diagnostics. He is recipient of the Academy for Radiology &Biomedical Imaging Research (ARBIR) Distinguished Investigator Award; MIT TR-35 Award; Harvard Medical School-Young Investigator Award; Stanford Basic Scientist of the Year Award; Brigham and Women’s Hospital-Bright Future Award; IEEE EMBS Early Career Award; IEEE EMBS Translational Science Award; NSF CAREER Award; Coulter Foundation Early Career Award; and Chinese International Young Scientist Award. He holds 25 issued or pending patents, provisionals, and disclosures that have been licensed to companies. He has published 146 articles, 24 book chapters/editorials, and 4 edited books, and serves as an editorial board member for various peer-reviewed journals. Dr. Demirci is also a fellow-elect of American Institute of Medical and Biological Engineering (AIMBE).



John Jain, MD is the CEO and Medical Director of Santa Monica Fertility. Dr. Jain completed medical school, residency and Fellowship in Reproductive Endocrinology and Infertility at the University of Southern California (USC) before joining the medical faculty in the Department of Obstetrics and Gynecology. While on faculty Dr. Jain served as the Associate Director of the American Board Fellowship in Reproductive Endocrinology and Infertility and Fellowship Director for the Kenneth Ryan Fellowship in Contraception.

While at USC, Dr. Jain received over $8M in federal and industry grants. Among these were RO1 grants from the NIH and industry grants from Pharmacia, Pfizer and other well-known pharmaceutical leaders studying the clinical effects of various steroids on contraception and bleeding. Dr. Jain served three years on the Small Business Innovative Research (SBIR) committee of the NIH reviewing dozens of biotechnology grants for federal funding as well as several study groups in the Institute of Child Health and Human Development and as an advisor on the inaugural committee on fertility preservation co-sponsored by the National Cancer Institute. Dr. Jain also served on the Advisory Board of the Buffet Foundation Kenneth Ryan Fellowship.

Dr. Jain has published over 100 scientific works including landmark articles in the New England Journal of Medicine and Journal of the American Medical Association. He was the first to publish results of a clinical trial on oocyte cryopreservation which ultimately led to an invitation to debate the topic of oocyte cryopreservation at the annual meeting of the American Society of Reproductive Medicine in 2009. Dr. Jain created the egg freezing program at USC and founded The Donor Egg Bank in 2004, one of the first frozen donor egg banks in the world.

Dr. Jain left his tenured position at USC in 2007 to establish Santa Monica Fertility located in Santa Monica, California. Over the past decade Dr. Jain built Santa Monica Fertility into an internationally recognized center specializing in egg donation and surrogacy with annual sales over $25M. This growth was facilitated by Dr. Jain’s footprint on American television, having appeared on over 15 nationally broadcasted shows including the Today Show, CNN, Dr. Oz, and the Doctors and being featured in the 2012 PBS Documentary My Future Baby, an award-nominated, nationally broadcasted documentary on the state of modern infertility treatment.

Santa Monica Fertility was partly acquired by Webster Capital Partners in 2019. Webster subsequently acquired 7 other high-quality fertility clinics in key fertility markets in the US. These companies have been reorganized under Pinnacle Fertility now established as one of the largest fertility platforms in the US accounting for over 10,000 annual ART cycles. Dr. Jain is a member of the Board of Directors of Pinnacle Fertility. In this role, he primarily provides insight on the clinical and lab practice of ART and advises on integration of various ancillary services and products. Dr. Jain is also the Founder of Novantacinque, a hospitality company with properties in the U.S. and Europe. Its first restaurant, Saso, was named one of the best new restaurants in Los Angeles in addition to being named on other international lists.



A serial investor in several healthcare technology startups, Ufuk Eren is the Founding Partner and CEO of Volitan Global. Volitan Global is based in 10 countries on 3 continents and is focused on technologies, innovation management, investment and M&A-like consulting services in the healthcare and life sciences sectors. Since July 2014, Mr. Eren has also held leading roles at Ernst & Young (EY) as Healthcare and Life Sciences Sector Leader for Turkey and Healthcare Sector Senior Advisor for Central, East, Southeast Europe and Central Asia (CESA). Mr. Eren has also been the Senior Advisor for the Healthcare and Life Sciences Sectors for Vodafone since October 2017.

From April 2014 to August 2016, Mr. Eren was Senior Advisor to the Royal Academy of Science International Trust (RASIT). In parallel, Mr. Eren was the founding partner and CEO of UK-based UN Innovation Development (UNID) company between June 2014 and August 2016. Mr. Eren had an active role in the “Women’s Health and Development Forum” organization, under the sponsorship of the United Nations together with UNID and RASIT in February 2015 at United Nations headquarters in New York City.

Throughout his career, Mr. Eren has held a number of senior leadership positions within the healthcare industry. Prior to his 20-year tenure with Siemens, he held management roles at International Hospital, Turkey and Canton Hospital in St. Gallen (KSSG), Switzerland. At Siemens, Mr. Eren held various roles such as CEO of the Clinical Products Division for Central Eastern Europe (CEE) and the Russia & Central Asia (RCA) Regions, CEO of South Asia Region, CEO of Siemens Healthcare Eastern Mediterranean Cluster and General Manager of Siemens Healthcare Turkey. Mr. Eren designed and implemented a training initiative as “Siemens Academy” which certified more than 1,000 professionals in the areas of “Health Management, Energy, Automation and Electrical Industries”. During his Siemens tenure, he established the Hospital Solutions Business, offering turn-key hospital solutions.

In 2013, Mr. Eren joined the Acıbadem Healthcare Group – part of IHH (the world’s second largest hospital group) as a member of the Executive Committee and assumed responsibilities such as Acıbadem’s investments and global growth, management of laboratory companies, strategy development for public-private partnership (PPP) projects and developing new business models. In addition, Mr. Eren has held various executive positions in a number of non-governmental organizations throughout his career and continues to actively pursue such opportunities.

Mr. Eren contributes to the realization of the visionary meetings for the development of the healthcare sector in Turkey at TUSAP (Turkish Healthcare Platform) of which he is among the founders and is currently a member of the Executive Committee. He also gives Health Economics and Entrepreneurship lectures as a visiting professor at Bahcesehir University Health Sciences Institute and is a member of the Advisory Board at Hacettepe University Health Economics and Health Policies Research and Implementation Center.